Biochem/physiol Actions

PF-06250112 is a potent inhibitor of Bruton′s tyrosine kinase (BTK). PF-06250112 blocks both B-cell receptor and FcR-mediated signaling, and prevents FcR-dependent, Antibody-mediated proteinuria in a mouse glomerulonephritis model.

Features and Benefits

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

Other Notes

This compound was developed by Pfizer for Kinase Phosphatase Biology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.